ProQR Therapeutics (PRQR) EBT (2013 - 2025)

ProQR Therapeutics (PRQR) has 13 years of EBT data on file, last reported at -$11.7 million in Q4 2025.

• For the quarter ending Q4 2025, EBT fell 27.33% year-over-year to -$11.7 million; the trailing twelve-month figure through Dec 2025 stood at -$48.9 million (down 65.78% YoY), and the FY2025 full-year result was -$50.4 million, down 73.1% from the prior year.
• EBT grew to -$11.7 million in Q4 2025, from -$12.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$3.1 million in Q2 2024 to a low of -$23.4 million in Q3 2022.
• A 5-year average of -$12.5 million and a median of -$12.3 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT jumped 74.62% in 2023 and sank 342.01% in 2025, its largest moves.
• Tracing PRQR's EBT over 5 years: stood at -$20.8 million in 2021, then soared by 38.25% to -$12.9 million in 2022, then jumped by 43.15% to -$7.3 million in 2023, then decreased by 25.24% to -$9.2 million in 2024, then fell by 27.33% to -$11.7 million in 2025.
• Business Quant data shows PRQR's EBT at -$11.7 million in Q4 2025, -$12.9 million in Q3 2025, and -$13.8 million in Q2 2025.